Hyperion DeFi Inc

Hyperion DeFi Inc(HYPD)股票分析

$2.510

-0.049 (-1.95%)收盤時

Loading chart…
最高
2.671
開盤
2.600
成交量加權均價
2.51
成交量
427.17K
市值
—
最低
2.360
成交金額
1.07M
企業價值/稅息折舊攤銷前利潤(TTM)
-0.88

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.

AI 分析 of Hyperion DeFi Inc (HYPD)

買進

Hyperion DeFi Inc is a good buy right now due to its recent positive developments and strong growth potential. The stock is currently priced at $3.29, significantly below its 52-week high of $6.48, indicating a potential for recovery. Additionally, the company has raised its 2026 adjusted gross profit guidance from $5 million to a new range of $7 million to $8 million, showcasing its improving financial outlook. However, investors should be cautious of the high volatility, as the stock has experienced a 49.83% decline over the past year, which poses a risk.

估值指標

Hyperion DeFi Inc(HYPD)目前預期本益比為 0.00,5 年平均預期本益比為 -0.57。

預期本益比

嚴重高估
5 年均值 P/E
-0.57
目前P/E
0.00
高估
-0.41
低估
-0.73

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-0.82
目前EV/EBITDA
-0.88
高估
-0.30
低估
-1.35

預期股價營收比

低估
5 年均值 P/S
13.87
目前P/S
6.77
高估
18.67
低估
9.06

事件時間軸

2026-10-02 (ET)

10:00:00

Coinbase Receives CFTC Approval for Derivatives Clearing

08:30:00

Hyperion DeFi Repurchases 240,124 HYPD Shares and Retires $8.6M Debt

2026-09-28 (ET)

09:30:00

Hyperion DeFi Named Launch Partner for Frontier's Hyperliquid Vault

2026-09-11 (ET)

10:00:00

Nasdaq to Invest $100M in Payward

2026-09-08 (ET)

09:00:00

Hyperion DeFi Launches $20M Share Buyback Program

資訊

HYPD 常見問題 —— 由 Alphio AI 解答

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles. It operates in the Healthcare sector.

Hyperion DeFi Inc is a good buy right now due to its recent positive developments and strong growth potential. The stock is currently priced at $3.29, significantly below its 52-week high of $6.48, indicating a potential for recovery. Additionally, the company has raised its 2026 adjusted gross profit guidance from $5 million to a new range of $7 million to $8 million, showcasing its improving financial outlook. However, investors should be cautious of the high volatility, as the stock has experienced a 49.83% decline over the past year, which poses a risk.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易